Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for prostaglandin transporter inhibition and related therapeutic applications

a prostaglandin transporter and inhibitor technology, applied in the field of compositions for inhibiting the prostaglandin transporter (pgt), can solve the problems of increasing side effects of synthetic drugs

Active Publication Date: 2020-12-10
SAMI LABS LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a natural plant-based composition that can be used as a prostaglandin transporter inhibitor. The composition contains specific amounts of several plants, including Allium sativum, Beta vulgaris, Nigella sativa, and Terminalia arjuna. The composition has therapeutic benefits in managing hypertension and conferring cardio protection in mammals. The technical effect is a safe and effective natural treatment for these conditions.

Problems solved by technology

However, these synthetic drugs have increased side effects and there exists a need for a safe and natural alternative to mitigate the effects of PGs by inhibiting PGT.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for prostaglandin transporter inhibition and related therapeutic applications
  • Composition for prostaglandin transporter inhibition and related therapeutic applications
  • Composition for prostaglandin transporter inhibition and related therapeutic applications

Examples

Experimental program
Comparison scheme
Effect test

example 1

f the Composition

[0037]The invention discloses a composition comprising 30-60% w / w Allium sativum extract, 10-30% w / w Beta vulgaris extract, 5-15% w / w Nigella saliva extract and 10-30% w / w Terminalia arjuna extract for the inhibition of PGT. The abovementioned extracts are reported to elicit cardioprotective and anti-hypertensive effects individually. Some of the medicinal properties of the above extracts are mentioned herein below:

[0038]Allium salivum is a well known plant used in the traditional system of Ayurveda. It is reported to elicit many therapeutic effects against different disorders which include cardiovascular diseases, regulating blood pressure, lowering blood sugar and cholesterol levels. It is also effective against bacterial, viral, fungal and parasitic infections and is reported to enhance the immune system. The plant also has anti-tumor properties (Ayaz and Alpsoy, Garlic (Allium sativum) and traditional medicine, Turkiye Parazitol Derg. 2007; 31(2):145-9). It hous...

example 2

n of Prostaglandin Transporter

[0043]The formulation was evaluated for its effect inhibiting the prostaglandin transporter (PGT). Kidney cell line, MDCK were seeded onto six-well plates at 30% confluence. Three days later, they were treated with 10 μM bradykinin (to increase endogenous PGE2 synthesis, available in Sigma-Aldrich) in the presence of vehicle (DMSO) at 37° C. for various durations. The formulation was added at graded concentration simultaneously to the cell culture and it was further incubated for 24 hours. Media were collected for measurements of extracellular concentrations of PGE2. Cells were washed with phosphate-buffered saline twice, lysed with 250 μl of phosphate-buffered saline containing 0.1 M HCl and 0.1% Triton X-100 at room temperature for 15 min, and scraped off the plates. Cell suspensions were pipetted up and down for several times to ensure thorough lysing. Cell lysates were collected and centrifuged at 10,000 g 4° C. for 10 min. Supernatants were collect...

example 3

rtensive Effects of the Formulation

[0048]Methods

[0049]Normotensive wistar rats were used for the experiments. The rats were spontaneously induced hypertension by the administration of DOCA (deoxycorticosterone acetate) a synthetic mineralocorticoid derivative, 25 mg / kg s.c. twice a week and 1% w / v NaCl in drinking water for a period of 30 days (Model: DOCA salt induced hypertension in rats). The rats were divided into the following groups containing 6 each:

TABLE 2GroupingGroupDescriptionINormal ControlIISalt loadedIIIFormulation at 50 mg / kg bodyweightIVFormulation at 100 mg / kg bodyweightVFormulation at 200 mg / kg bodyweightVIFormulation at 400 mg / kg bodyweight

[0050]The following parameters were estimated to evaluate the anti-hypertensive effects of the formulation[0051]Expression of PGT[0052]Nitric oxide estimation[0053]Blood Pressure[0054]Heart Rate[0055]Mean Arterial Pressure[0056]Urine Volume

[0057]Expression of PGT

[0058]Solute carrier organic anion transporter family, member 2A1 i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
systolic and diastolic pressureaaaaaaaaaa
pressureaaaaaaaaaa
diastolic pressureaaaaaaaaaa
Login to View More

Abstract

The present invention discloses a composition comprising Allium sativum extract standardized to contain not less that 0.3% w / w S-allylcysteine, Beta vulgaris extract standardized to contain not less than 2% w / w nitrates, Nigella sativa extract standardized to contain 0.1%-5% w / w thymoquinone, about 0.01%-10% w / w thymohydroquinone, about 20%-95% w / w fatty acids, about 0.001%-3% w / w α-hederin or hederagenin, and Terminalia arjuna extract standardized to contain 3% w / w arjunoglucosides for use a prostaglandin transporter inhibitor. The invention also discloses the use of the aforementioned composition in the therapeutic management of hypertension and cardiovascular complications.

Description

FIELD OF INVENTION[0001]The invention in general relates to composition comprising plant extracts. More specifically the present invention pertains to compositions for inhibiting prostaglandin transporter (PGT) and related therapeutic applications.BACKGROUND OF THE INVENTION[0002]Prostaglandins (PGs) are naturally occurring unsaturated fatty acids which are implicated in mediating a variety of pathophysiological processes and homeostatic functions in different organs. They are derived from arachidonic acid by the action of cyclooxygenase isoenzymes. Principally, there are 4 bioactive PGs ubiquitously produced: prostaglandin E2 (PGE2), prostacyclin (PGI2), prostaglandin D2 (PGD2), and prostaglandin F2α (PGF2α), acting as autocrine and paracrine mediators to maintain homeoastatic functions in the body (Ricciotti et al., Prostaglandins and Inflammation, Arteriosclerosis, Thrombosis, and Vascular Biology. 2011; 31:986-1000). PGs play a main role in regulating many disease conditions in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K36/88A61K36/21A61K36/71A61K36/185A61K31/197A61K31/122A61K31/704A61K31/192A61P9/12
CPCA61K31/704A61K31/192A61K31/122A61K36/88A61P9/12A61K36/71A61K36/185A61K36/21A61K31/197A61K36/8962A61K2300/00
Inventor MAJEED, MUHAMMEDNAGABHUSHANAM, KALYANAMBANI, SARANGPANDEY, ANJALI
Owner SAMI LABS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com